HTLV-1 proviral genes detected in CD34+ HP/HSCs from patients
| Patient details . | Viral copies per 106 PBMCs* . | HTLV-1 proviral genes detected in purified CD34+ cells† . | Clinical diagnosis . | |||
|---|---|---|---|---|---|---|
| ID . | Age, y/sex . | Gag . | Env . | Tax . | ||
| Uninfected | 31/male | ND | − | − | − | None |
| 7854/5885 | ND/ND | ND | ++ | − | ++ | HTLV-1 asymptomatic carrier |
| DB-14 (2 samples) | ND/female | 0 | − | − | − | HTLV-1, asymptomatic carrier |
| AT PBLS | ND/female | ND | − | + | ++ | HTLV-1, TSP/HAM |
| MCB | ND/ND | ND | + | + | ++ | TSP/HAM |
| NXB | ND/ND | ND | − | + | ++ | TSP/HAM |
| LXA | ND/ND | ND | + | + | ++ | TSP/HAM |
| WJ (3 samples) | ND/female | 18 112 | + | + | + | HTLV-1, myelopathy |
| 224/GS (2 samples) | 47/female | 205 000 | ++ | ++ | ++ | HTLV-1, uveitis |
| 6 | 45/female | 598 574 | − | ++ | ++ | HIV/HTLV-1, asymptomatic |
| 261 | 60/male | 501 272 | + | ++ | ++ | HIV/HTLV-1, asymptomatic |
| 88 | 72/male | 77 501 | − | ++ | ++ | HIV/HTLV-1, peripheral neuropathy |
| 154 | 38/female | 29 333 | − | ++ | ++ | HIV/HTLV-2, peripheral neuropathy |
| 76 | 45/male | 404 692 | ++ | ++ | ++ | HIV/HTLV-1, gait ataxia |
| 93 | 47/male | 328 507 | ++ | ++ | ND | HIV-1/HTLV-1, stroke |
| Patient details . | Viral copies per 106 PBMCs* . | HTLV-1 proviral genes detected in purified CD34+ cells† . | Clinical diagnosis . | |||
|---|---|---|---|---|---|---|
| ID . | Age, y/sex . | Gag . | Env . | Tax . | ||
| Uninfected | 31/male | ND | − | − | − | None |
| 7854/5885 | ND/ND | ND | ++ | − | ++ | HTLV-1 asymptomatic carrier |
| DB-14 (2 samples) | ND/female | 0 | − | − | − | HTLV-1, asymptomatic carrier |
| AT PBLS | ND/female | ND | − | + | ++ | HTLV-1, TSP/HAM |
| MCB | ND/ND | ND | + | + | ++ | TSP/HAM |
| NXB | ND/ND | ND | − | + | ++ | TSP/HAM |
| LXA | ND/ND | ND | + | + | ++ | TSP/HAM |
| WJ (3 samples) | ND/female | 18 112 | + | + | + | HTLV-1, myelopathy |
| 224/GS (2 samples) | 47/female | 205 000 | ++ | ++ | ++ | HTLV-1, uveitis |
| 6 | 45/female | 598 574 | − | ++ | ++ | HIV/HTLV-1, asymptomatic |
| 261 | 60/male | 501 272 | + | ++ | ++ | HIV/HTLV-1, asymptomatic |
| 88 | 72/male | 77 501 | − | ++ | ++ | HIV/HTLV-1, peripheral neuropathy |
| 154 | 38/female | 29 333 | − | ++ | ++ | HIV/HTLV-2, peripheral neuropathy |
| 76 | 45/male | 404 692 | ++ | ++ | ++ | HIV/HTLV-1, gait ataxia |
| 93 | 47/male | 328 507 | ++ | ++ | ND | HIV-1/HTLV-1, stroke |
CD34+ cells were purified by fluorescence-activated cell sorting from a total of 105 to 106 PBMCs from patients. The percentage of CD34+ cells ranged from 0.3% to 1.0% of total PBMCs. High-molecular-weight DNA was isolated and analyzed by PCR for individual HTLV genes.
HP/HSCs indicates hematopoietic progenitor/stem cells; HTLV-1, human T-lymphotropic virus type 1; ND, no data available; PBMCs, peripheral blood mononuclear cells; PCR, polymerase chain reaction; TSP/HAM, tropical spastic paraparesis/human T-lymphotropic virus type I–associated myelopathy; −, < 1 viral gene copy detected per 103 human cells; +, 1 viral copy per 1-103 human cells; and ++, > 1 viral copy per 1 human cell.
HTLV virus load per 1 × 106 patient PBMCs.
Mean of HTLV-1 proviral copies calculated per CD34+ cell, purified by fluorescence-activated cell sorting.